Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post-hoc analysis of a large clinical trial safety database
Haematologica. 2024 Feb 29.
doi: 10.3324/haematol.2023.283846.
Online ahead of print.
1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA. Jennifer_Brown@dfci.harvard.edu.
2 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan.
3 Maria Skłodowska-Curie National Research Institute of Oncology, Kraków.
4 Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
5 Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY.
6 Medical University of Łódź, Łódź.
7 Fred Hutchinson Cancer Research Center, Seattle, WA.
8 Alfred Hospital and Monash University, Melbourne, VIC.
9 State Key Laboratory of Experimental Hematology, National Clinical Medical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin.
10 BeiGene USA, Inc, San Mateo, CA.
11 BeiGene International GmbH, Basel.
12 BeiGene (Shanghai) Co, Ltd, Shanghai.
13 ASST Grande Ospedale Metropolitano Niguarda, Milan.